Calls are growing to slash the reimbursement price of Ono Pharmaceutical’s immuno-oncology drug Opdivo (nivolumab) as a member of a key panel on October 14 leaned on the government to ax it by more than 50%. At a meeting of…
To read the full story
Related Article
- Govt Panel Members Call for Drastic Drug Pricing Reform, Annual Revision
October 24, 2016
- Key Govt Panel Sets Sights on Pricy Meds
August 9, 2016
REGULATORY
- MHLW Taps Kawabata to Lead Drug Discovery Support Office
April 15, 2026
- MHLW Reviewing EMIS Data on Petro-Product Supply to Medical Institutions
April 15, 2026
- Japan Panel to Review Ferring Gene Therapy, Fujifilm Cell Product on April 20
April 14, 2026
- LDP, Ishin to Explore Role of Private Insurance in Reform Talks
April 14, 2026
- Middle East War Hitting API Air Freight, Trade Group Warns
April 13, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





